
ÀÇ·áÁø¼Ò°³
¹®¾È°ú ÀÇ·áÁøÀº ü°èÀûÀÎ ½Ã½ºÅÛÀ¸·Î
ÃÖ¼±ÀÇ Áø·á¸¦ Á¦°øÇÕ´Ï´Ù.
ÀÇÇйڻç / ¾È°úÀü¹®ÀÇ / ½Ã·Â±³Á¤,¼ºÇü¾È°ú Àü¹®ÀÇ
¡¤ ¹®¾È°ú ´ëÇ¥¿øÀåÁÖ¿äÇØ¿Ü ¿¬¼ö ¹× ÇÐȸ¹ßÇ¥
¡¤ 1991 USA Anaheim ¹Ì±¹¾È°úÇÐȸ¼Ò¼ÓÇÐȸ
¡¤ ´ëÇÑ ¾È°úÇÐȸ Á¤È¸¿ø¸Á¸·¼¾ÅÍÀå / ¾È°úÀü¹®ÀÇ / ¸Á¸·Àü¹®ÀÇ / Çѱ¹¸Á¸·ÇÐȸÁ¤È¸¿ø
¡¤ ¼¿ï´ëÇб³ Àǰú´ëÇÐ ÀÇÇйڻç°úÁ¤¼Ò¼ÓÇÐȸ
¡¤ Çѱ¹¸Á¸·ÇÐȸ º¸ÇèÀ§¿ø / ¼ö¿ø½ÃÀÇ»çȸ Àǹ«ÀÌ»çÁÖ¿äÇÐȸ¹ßÇ¥
¡¤ 2014 ARVO in Orlando / 2015 AAO in Las VegasÁÖ¿ä³í¹® : (SCI ³í¹® Á¦1ÀúÀÚ,Ã¥ÀÓÀúÀÚ¸¸ ±âÀç,Àü¼¼°è Top3 ¾È°ú³í¹® 10¿©Æí, ¸ñ·Ï÷ºÎ)
¡¤ ¸Á¸·³»Ãþ ºÒ±ÔÄ¢ Áö¼ö¸¦ ÀÌ¿ëÇÑ ¸Á¸·Àü¸·ÀÇ ¿¹ÈÄ ¿¹Ãø - ¹Ì±¹¾È°úÀú³Î(AJO) 2016ÃÖ±Ù SCI ³í¹® ¸ñ·Ï (Á¦ 1ÀúÀÚ, Ã¥ÀÓÀúÀÚ¸¸ ±âÀç)
1. Kim MS, Moon JH, Lee MW, Cho KH (2022), Analysis of postoperative intraocular pathologies in patients with mature cataracts. PLoS ONE 17(1): e0263352.ÀÇÇйڻç/¾È°ú-³ì³»ÀåÀü¹®ÀÇ/Çѱ¹³ì³»ÀåÇÐȸ Á¤È¸¿ø
¡¤ ¼¿ï´ëÇб³ Àǰú´ëÇÐ ÀÇÇйڻç/ÀÇÇм®»ç/ÀÇÇлç¼Ò¼ÓÇÐȸ
¡¤ ´ëÇѾȰúÇÐȸ(KOS)/Çѱ¹³ì³»ÀåÇÐȸ(KGS) Á¤È¸¿øÁÖ¿ä ÇмúȰµ¿
¡¤ ¼¼°è³ì³»ÀåÇÐȸ(WGC), ÀϺ»³ì³»ÀåÇÐȸ(JGS), ű¹³ì³»ÀåÇÐȸ(TGC) µî ´Ù¼ö ±¹Á¦ÇÐȸ ÃÊû °¿¬ÁÖ¿ä³í¹®
³ì³»Àå Á¶±âÁø´Ü°ú Á¤È®ÇÑ °¨º°, ³ì³»Àå ÁøÇà ºÐ¼® ¹× Ä¡·á ÁÖÁ¦·Î ¾È°úÇÐ ºÐ¾ß ÃÖ°í ±¹Á¦ÇмúÁöOphthalmology Àú³Î (Impact Factor 14.277) µî SCI ±¹Á¦ÇмúÁö¿¡ ÁÖÀúÀÚ·Î 30¿©Æí ÃâÆÇ (°øÀúÀÚ Æ÷ÇÔ 70¿©Æí)ÃÖ±Ù SCI ³í¹® ¸ñ·Ï (ÃÖ±Ù 3³â ÁÖÀúÀÚ¸¸ ±âÀç)
Ã¥ÀÓÀúÀÚÀÇÇйڻç / ¾È°úÀü¹®ÀÇ / Àü¾ÈºÎÀü¹®ÀÇ
¡¤ ¼¿ï¾Æ»êº´¿ø ¿ï»ê´ëÇб³ Àǰú´ëÇÐ ¾È°úÇб³½Ç ÀÇÇйڻç¼Ò¼ÓÇÐȸ
¡¤ ´ëÇѾȰúÇÐȸ Á¤È¸¿øÁÖ¿äÇÐȸȰµ¿
¡¤ 2015 AAO(¹Ì±¹¾È°úÇÐȸ) in Las VegasÀÇÇм®»ç / ¾È°úÀü¹®ÀÇ / ¸Á¸·Àü¹®ÀÇ
¡¤ ¼¿ï¾Æ»êº´¿ø ¿ï»ê´ëÇб³ Àǰú´ëÇÐ ¾È°úÇб³½Ç ¿Ü·¡Á¶±³¼ö¼Ò¼ÓÇÐȸ
¡¤ ´ëÇѾȰúÇÐȸÁÖ¿äÇÐȸ¹ßÇ¥ (1ÀúÀÚ ¹ßÇ¥)
¡¤ 2017 ¹Ì±¹¾È°úÇÐȸ (ARVO) in BaltimoreÁÖ¿ä³í¹® (1ÀúÀÚ)
1. Park YJ, Lee S, Yoon YH. One-year follow-up of optical coherence tomography angiography microvascular findings: macular telangiectasia type 2 versus tamoxifen retinopathy. Graefes Arch Clin Exp Ophthalmol 2022ÀÇÇм®»ç / ¾È°úÀü¹®ÀÇ / ¸Á¸·Àü¹®ÀÇ
¡¤ ¼¿ï´ëÇб³ Àǰú´ëÇÐ ¾È°úÇб³½Ç ¸Á¸·Àü¹®ÀǼҼÓÇÐȸ
¡¤ ´ëÇѾȰúÇÐȸÁÖ¿äÇÐȸȰµ¿
¡¤ 2016 ¹Ì±¹¾È°úÇÐȸ (AAO) in ChicagoÁÖ¿ä³í¹® (1ÀúÀÚ)
1. Choe HR, Yang HK, Hwang JM, Long-term outcomes of prismatic correction in partially accommodative esotropia. PLoS One. 2019;14(12):e0225654.¾È°úÀü¹®ÀÇ / ¸Á¸·Àü¹®ÀÇ
¡¤ ¼¿ï´ëÇб³ Àǰú´ëÇÐ ¾È°úÇб³½Ç ÀÓ»ó°»ç¼Ò¼ÓÇÐȸ
¡¤ ´ëÇѾȰúÇÐȸ Á¤È¸¿øÁÖ¿äÇÐȸȰµ¿
¡¤ 2016 ARVO in USA, SeattleÁÖ¿ä³í¹® (1ÀúÀÚ)
1. Jin KW, Kim DJ, Han JM, Lee SH, Park YS, Lee JY, Lee EK, Lee JS, Kim ST, Shin MH, Lee CS, Jung HH, Jang JY, Kim M, Kim YH, Kim JH, Park KH, Park SJ, Joo K, Ji YS, Sagong M, Woo SJ. Short-term safety and efficacy of intravitreal brolucizumab injections for neovascular age-related macular degeneration: a multicenter retrospective real-world study. Ophthalmologica. 2023.¾È°úÀü¹®ÀÇ / Àü¾ÈºÎÀü¹®ÀÇ
¡¤ ÇѸ²´ëÇб³ °³²¼º½Éº´¿ø ¾È°úÀü¹®ÀǼҼÓÇÐȸ
¡¤ ´ëÇѾȰúÇÐȸ Á¤È¸¿øÁÖ¿äÇÐȸ¹ßÇ¥ (1ÀúÀÚ ¹ßÇ¥)
¡¤ 2018 ´ëÇѾȰúÇÐȸ Ãá°è »ç½Ã Æ÷½ºÅÍ ¹ßÇ¥ÁÖ¿ä³í¹® (1ÀúÀÚ)
Choi JJ,Kim HK, Yi K, Comparison of the Accuracies of Intraocular Lens Power Formulae by the Type of Implanted Lens. J Korean Ophthalmol Soc 2021;62(3):315-321.¾È°úÀü¹®ÀÇ / ´ëÇѾȰúÇÐȸ Á¤È¸¿ø / Àü¾ÈºÎÀü¹®ÀÇ
¡¤ ¿¬¼¼´ëÇб³ Àǰú´ëÇÐ °³²¼¼ºê¶õ½ºº´¿ø Àü¾ÈºÎ Àü¹®ÀǼҼÓÇÐȸ
¡¤ ´ëÇѾȰúÇÐȸ Á¤È¸¿ø / Çѱ¹¹é³»Àå±¼Àý¼ö¼úÇÐȸ Á¤È¸¿øÁÖ¿äÇÐȸ¹ßÇ¥ (1ÀúÀÚ ¹ßÇ¥)
¡¤ 2016 ARVO in Seattle, USÁÖ¿ä³í¹® (1ÀúÀÚ)
1. Comparison of ocular surface mucin expression after topical ophthalmic drug administration in dry eye-induced mouse model, J Ocul Pharmacol Ther. 2018 Nov:34(9):612-620.ÀÇÇйڻç / ¾È°úÀü¹®ÀÇ / Àü¾ÈºÎÀü¹®ÀÇ
¡¤ ¼¿ï¾Æ»êº´¿ø ¿ï»ê´ëÇб³ Àǰú´ëÇÐ ¾È°úÇб³½Ç Àü¾ÈºÎÀü¹®ÀǼҼÓÇÐȸ
¡¤ ´ëÇѾȰúÇÐȸÁÖ¿äÇÐȸȰµ¿
¡¤ 2018 ´ëÇоȰúÇÐȸ Ãß°è ÄÜÅÃÆ®·»Áî ±¸¿¬ ¹× ¹é³»Àå ±¼Àý ¼ö¼ú, ³ì³»Àå Æ÷½ºÅÍ ¹ßÇ¥ÁÖ¿ä³í¹®
1. Effect of Postoperative Trimming of the Tube Portion of Ahmed Glaucoma Valve on Corneal Endothelial Cell Loss, Journal of Glaucoma, 2022¹®¾È°ú¼Ò°³
½º¸¶À϶ó½Ä-¶ó¼½¼¾ÅÍ
³ë¾È¡¤¹é³»Àå¼¾ÅÍ
¸Á¸·¼¾ÅÍ
³ì³»Àå¼¾ÅÍ
¼ºÇü¾È°ú¼¾ÅÍ
µå¸²·»Áî
»ó´ã/¿¹¾à
Member